Risk of Thromboembolic Events With COVID-19: A Sentinel System Investigation – Potential Aims/Methods

This presentation was given at the Reagan-Udall Foundation and Friends of Cancer Research COVID-19 Diagnostics Evidence Accelerator Parallel Analysis meeting by Vincent Lo Re from the University of Pennsylvania on behalf of the FDA Sentinel COVID-19 Coagulopathy workgroup. It includes the potential aims and methodology for “Descriptive Assessment of Coagulopathy Among COVID-19 Patients in the Inpatient Setting: A Sentinel Feasibility Study,” with a focus on thrombotic complications such as venous and arterial thromboses.